Logistics 4.0. and the Challenge of the Last Mile in the Health Sector Oscar Perez oscar.perez@movianto.com
Disclaimer Confidential and Proprietary to OM Movianto, an Owens & Minor Company. This presentation is provided for informational purposes only, Customers should consult with OM Movianto before making purchasing or contracting decisions. 2
Agenda Evolution and change in the Health Industry Complexity in the SC Direct to Patient Model 3
Evolution of the Health Industry Commercial Implications Fragmented Portfolio New Challenges Pipeline Results in Patients Borders and Price Predictability of Demand Stock-management Special Requirements Consolidations / Acquisitions Reverse Logistics Last Mile Solution 4
Changes: Regulations New GDP s Serialisation Chapter 9: Transportation 9.1 Principle It is the responsibility of the wholesale distributor to protect the drugs from tampering, adulteration and theft, as well as ensuring that they are acceptable during transportation. Irrespective of the mode of transport, it must be possible to demonstrate that the medicinal products have not been exposed to conditions that could endanger their quality and integrity. A riskbased approach should be used when planning transportation. 9.2 Transportation The storage conditions required for the medicinal products must be maintained during transport within the limits defined in the manufacturer's description or on the outer packaging.
Supply Chain Complexity Extension of the Hospital Capture Patient Results Polarisation of the Product Portfolio Product Pipeline Adherence & Persistence Taxation Removal of Intermediaries Stopping the One rule for all Control of the SC
Types and Destinations Medication for Human Use Veterinary Medicines Medical Devices Classes I, IIa, IIb, III Health and Beauty Wholesaler Hospital Pharmacy Patient
The Patient Experience 8 Personalised Treatment Mobility? Convenience EXPECTATIONS BENEFITS Delivery Not in the Hospital Increase Adherance Data Protection Privacy Pharmacovigilance & Support
Pharmacy Competitive Situation Sustainable costs? Pharmacy Prescription registration & Repetition Convenience
Laboratory Key Factors N Patient Services Market Share Economy UK GERMANY POLAND BENELUX SPAIN Value Added Services (Stock Rotation ) Repeated Patient Deliveries
UK Model NHS Subcontracting to Service Providers Tax Benefits
Prescription Different Motivations Direct relationship with patient and treatment monitoring Cost Management (GB and VAT benefits) Skip to the wholesaler and / or pharmacy Geographical access Different Regulations National Markets Pressure Groups Publicly regulated requirements Compliance with laws Different Solutions Subcontractions Registration and prescription of the patient Direct to Hospital Clinical Trials
Unexpected consequences 13 Who owns the data? What can the data be used for? Who has the contract? Who is responsible? Who is it delivered to? How is the patient protected? What if the patient is not in? Privacy in systems and processes Be sure to provide the strict and necessary information Agreements with Third Parties Dispensing Error Delivery protocols - authorizations Product Integrity Unidentified vehicles and uniforms Preparation and management of deliveries
Evolution in Europe Pharmaceutical Products not Allowed Delivery through Hospital Pharmacy Hospital subcontracts to "home treatment providers" Private Prescription with Patient Services Tripartite Agreements: laboratory, hospital and service provider Online Prescription of electronic and doctor-by-video consultation
Final Summary Home deliveries in active in many countries for nonprescription products Products with prescription: restrictions. The process ensures: The patient has high expectations and low tolerance to failure Countries evolve at different levels Patient Confidentiality Value Added Services Hospitals are forcing change Privacy of Data Nursing Support Agreements between parties Pharmacovigilance Delivery Protocols Innovative thinking
Thank you Oscar Pérez oscar.perez@movianto.com